New Perspectives in CAD and PAD: Weighing the Latest Evidence

Slides:

Advertisements

Similar presentations

Addressing the Challenges in Primary and Secondary Stroke Prevention

Advertisements

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Oral Anticoagulation and Preventing Stent Thrombosis

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Access to NOAC Therapy:

NOACs in Clinical Practice: Are They All the Same?

Emergency Management of NOAC Bleeding

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Select Topics in Cardiovascular Medicine

Up to Date on Which NOAC for Which Patient

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Antiplatelet Therapy and Secondary Prevention

The Essentials for Secondary Stroke Prevention

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?

Treatment Options to Consider

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

NOACS: Emerging data in ACS/IHD

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Risk Stratification in CAD and PAD

Oral Anticoagulation in AF

Dos and Don’ts for High-Risk Elderly Patients With AF

Practical Considerations to Extend Treatment for VTE

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

CV Risk Doesn't End in the Cath Lab

Anticoagulation and Thrombosis Management

Duration of Dual Antiplatelet Therapy

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

Cancer-Associated Thrombosis

CAD and HF Often Coexist

A Case Challenge.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotic Therapy in PAD

Latest Perspectives in PAD: How to Improve Outcomes

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

Managing Pulmonary Embolism Posthospital Discharge

Antithrombotics in Arterial Disease: Focus on Coronary Disease

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Reassessing Risk Stratification in CAD/PAD

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Program Goals

Burden of CAD and PAD

REACH Registry

REACH Registry Economic Burden of PAD in the United States

Management of CAD and PAD Antithrombotic Strategies

CURE Dual Antiplatelet Therapy in Non-STE ACS

Dual Antiplatelet Strategies in CAD

Anticoagulant Therapy in CAD Warfarin -- WARIS-2

Warfarin + Aspirin after MI or ACS Meta-Analysis

Warfarin + Aspirin After ACS Meta-Analysis

Anticoagulant Therapy With NOACs in CAD Apixaban -- APPRAISE-2

Rivaroxaban ATLAS ACS-TIMI 46 -- Clinically Significant Bleeding

Rivaroxaban ATLAS ACS-TIMI 46 -- Efficacy Outcomes

Rivaroxaban: ATLAS ACS 2-TIMI 51

Rivaroxaban ATLAS ACS 2-TIMI 51-- Primary Efficacy Outcome

Rivaroxaban ATLAS ACS 2-TIMI 51 -- Bleeding Outcomes

Rivaroxaban COMPASS -- Trial Design

Rivaroxaban COMPASS -- Trial Design (cont)

COMPASS Efficacy Outcomes

COMPASS Bleeding Outcomes and Net Clinical Benefit

COMPASS PAD MALE and Major Amputation

Lessons Learned

Holistic Approach to Management

Tailoring Therapy

Summary

Abbreviations

Abbreviations (cont)